Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 5, 2026, a projected date rather than a confirmed one. There are 6 upcoming events on record.
Cash runway is approximately 5.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 12 concluded trials, 100% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 5, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| January 15, 2027 | A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) | Trial Milestone | Phase 2 |
| March 15, 2027 | Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy | Trial Milestone | Phase 2 |
| December 15, 2027 | A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF) | Trial Milestone | Phase 2 |
| December 15, 2027 | A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM) | Trial Milestone | Phase 2 |
| February 15, 2031 | Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | Trial Milestone | Phase 2 |
Track EWTX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open EWTX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.